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Adult neurogenesis, or the creation of new neurons in the adult brain, is an evolutionarily 
conserved process that occurs in both vertebrate and invertebrate species, from the neurogenic 
niche of the crayfish Procambarus clarkii to the subventricular zone of the olfactory bulb and 
subgranular zone of the hippocampus in humans. The mechanisms regulating adult neurogenesis 
are of interest to the medical community because of the promise of new drug targets and 
therapies for neurological disorders. Recent findings in P. clarkii have shown that neuronal 
precursors must be added to the niche from an extrinsic source because even though the pool of 
neuronal precursors in the niche is never depleted, the cells themselves are not self-renewing. In 
vitro and in vivo findings have shown that the immune system is likely the extrinsic source. Here, 
three protocols are used to extend these findings and to further characterize the relationship 
between the immune system and adult neurogenesis in P. clarkii. Cells labeled with 5-bromo-
2’deoxyuridine (BrdU) were quantified in the neurogenic niche and immune system tissues (the 
anterior proliferation center [APC] and posterior hematopoietic tissue [HPT]) at standardized 
time points over a 21 day period. In the first protocol, only BrdU was injected into the crayfish 
on day 0. In the second both BrdU and r-AST1, an immune system modulator, were injected on 
day 0, and in the third protocol, BrdU was injected on day 0 and r-AST1 was injected on day 1. 
The resulting data show that manipulating the immune system of P. clarkii alters the timeline by 
which neuronal precursors arrive in the neurogenic niche, demonstrating that neuronal precursors 































 The timeline by which new neurons are born and integrated into the brain’s complex 
circuitry has been highly disputed over the past hundred years, with dogma originally stating that 
animals are born with all of the neurons they will ever have. However, evidence has emerged 
over the last fifty years that shows that neurons are, in fact, created and functionally incorporated 
into electrical pathways throughout life in many animals. The phenomenon of adult 
neurogenesis, the creation of new neurons in the adult brain, is now acknowledged in the 
hippocampus and olfactory bulb of mammals, including humans (Kuhn, Dickinson-Anson et al. 
1996; Eriksson, Perfilieva et al. 1998).  Further, understanding the mechanisms underlying adult 
neurogenesis holds promise of new treatment targets for central nervous system diseases, 
including brain tumors and neurodegenerative diseases such as Parkinson’s and Alzheimer’s.  
 Neurons are born in the adult brains of a range of species, including invertebrates such as 
crustaceans. The present study seeks to confirm and to further specify the mechanisms by which 
new neurons are created in the adult brain by utilizing the crayfish Procambarus clarkii, a 
reliable invertebrate model system. Adult neurogenesis in crustaceans and in mammals is highly 
conserved, as demonstrated by the many parallels between these processes. For example, both 
crustaceans and mammals have a highly vascularized neurogenic niche and a defined precursor 
cell lineage composed of 3-4 cellular generations that is regulated by environmental cues, 
serotonin and nitric oxide (Sullivan, Sandeman et al. 2007; Beltz, Zhang et al. 2011). These and 
many other parallels suggest that discoveries pertaining to adult neurogenesis in the crayfish 
model may be applicable to adult neurogenesis in mammals. The current studies examine the 
relationship between the immune system and adult neurogenesis, and further test the finding that 




Adult neurogenesis: a controversial history  
 The phenomenon of adult neurogenesis in mammals was first demonstrated by Altman in 
the 1960s (Altman 1962). However, because adult-born neurons would have to integrate into the 
brain’s complex circuitry, a seeming impossibility considering the necessity of stable circuits to 
maintain function throughout life, the birth of neurons in the adult brain was widely rejected as a 
general occurrence by scientists until the 1990s (Gould, Reeves et al. 1999, Nottebohm 2002). In 
addition, many people who suffer brain injury due to stroke, trauma or aging never recover 
function, and thus the clinical picture also throws doubt into the possibility of adult neurogenesis.  
 However, as more efficient cell labeling techniques were developed that allowed 
researchers to track the birth of new neurons, the process of natural adult neurogenesis in many 
vertebrate and invertebrate species was slowly accepted. The original labeling methods involved 
3
H-thymidine incorporation and detection by autoradiography, which involved weeks or months 
of processing time (Altman 1962, Altman and Das 1965). In the 1990s, labeling with 5-bromo-
2’deoxyuridine (BrdU) followed by immunocytochemistry became the most popular method for 
labeling new neurons in the brain (Kuhn, Dickinson-Anson et al. 1996, Eriksson, Perfilieva et al. 
1998, Gould, Reeves et al. 1999). Most recently, methods utilizing viral introduction of green 
fluorescent protein (GFP)-vector (van Praag, Schinder et al. 2002; Carleton, Petreanu et al. 2003) 
and carbon-14 radiodating (Bhardwaj, Curtis et al. 2006) have been introduced. 
  In the first widely accepted example of adult neurogenesis, Nottebohm found newborn 
neurons in the high vocal center (HVC) of adult songbirds (Nottebohm 2002). Studies in rodents 
have since shown that chemically preventing neurogenesis in mice caused deterioration of the 
olfactory bulb, indicating that a constant addition of cells is required for the bulb’s integrity 




cells in the hippocampus increases, indicating that new cells are incorporated into the region 
throughout life. To prove the functionality of new neurons in the hippocampus, van Praag et al. 
(2002) used GFP-labeling methods to show that neurons born in adulthood are, in fact, 
electrically functional in the hippocampus, indicating that the new neurons are successfully 
integrated into the brain’s existing circuits (van Praag, Schinder et al. 2002). Further, Gould et al. 
(1999) demonstrated adult neurogenesis in the subventricular zone (SVZ) of macaque monkeys 
and Carleton et al. (2003) demonstrated functional incorporation of neurons generated in the 
SVZ in the olfactory bulb of mice (Gould, Reeves et al. 1999; Carleton, Petreanu et al. 2003) 
These authors, among others, collectively proved the existence of neuronal precursors underlying 
adult neurogenesis in the subgranular and subventricular zones in a variety of model systems,  
and have shown that these areas contribute new neurons to the hippocampus and olfactory bulb, 
respectively (Eriksson, Perfilieva et al. 1998; van Praag, Schinder et al. 2002; Imayoshi, 
Sakamoto et al. 2009). 
 
BrdU labeling to track adult neurogenesis 
BrdU labeling is one of the most effective methods by which to label newborn cells (used 
efficiently in Gould, Reeves et al. (1999) and Benton et al. (2014)) and is the method used in the 
present study. BrdU, a thymidine analog, is incorporated into the DNA of any cell that goes 
through S phase prior to the clearing time, which is the time it takes for the amount of BrdU in a 
system to dissipate enough such that the label incorporation no longer reaches detectable levels. 
BrdU is relatively easy to detect using immunohistochemical techniques. However, one potential 




diluting the label with each division, the label will eventually no longer be visible via 
immunohistochemistry in long cell lineages. 
 
Crayfish as a non-vertebrate model system for adult neurogenesis 
The crayfish is a relatively simple, effective model system for investigating adult 
neurogenesis. Crayfish possess bilateral neurogenic niches which are located on the ventral 
surface of the brain. Each end of the niche tapers 
into a migratory stream that leads to either the 
lateral proliferation zone (LPZ) of Cluster 10 or the 
medial proliferation zone (MPZ) of Cluster 9 
(Figure 1). Cells produced by the division of 1
st
-
generation neuronal precursors (functionally 
analogous to neural stem cells in mammals) in the 
niche traverse these migratory streams to cell 
clusters in the brain, where they will divide again and their descendants will differentiate into 
neurons. 
Previous experiments have shown that crustaceans undergo neurogenesis throughout their 
entire life span. Harzsch et al. (1999) demonstrated that Homarus americanus (lobster) 
undergoes life-long neurogenesis in the olfactory pathway and Sullivan and Beltz (2005) showed 
that the phenomenon occurs in Cluster 10 (containing olfractory interneurons) and in the visual 
system in the crayfish Cherax destructor (Sullivan and Beltz 2005). Thus, like mammals, in 
which the presence of adult neurogenesis has been confirmed in the olfactory bulb and 
hippocampus, the process has also been confirmed in a few, distinct locations in crustaceans: the 
Figure 1: Confocal microscopical image 
of the ventral side of the crayfish brain. 
This image shows the niche, migratory 
streams, medial and lateral proliferation 
zones and Clusters 9 and 10. Figure 




olfactory lobe (Harzsch, Miller et al. 1999), which is analogous to the mammalian olfactory bulb, 
and the accessory lobe (Sullivan and Beltz 2005), a center for higher order processing similar to 
the hippocampus, and the visual system (Chaga, Lignell et al. 1995; Sullivan and Beltz 2005; 
Benton, Chaves da Silva et al. 2013).   
The crayfish equivalent of mammalian neuronal stem cells, termed 1st-generation neuronal 
precursors, are located in the neurogenic niche (Sullivan, Sandeman et al. 2007). Unlike in 
mammals, BrdU labeling 




divide, both of the daughter 
cells migrate from the niche 
through the migratory streams 
and into the LPZ or MPZ 
associated with interneuron 
clusters 10 and 9, respectively 
(Figure 2) (Zhang, Allodi et 
al. 2009). In the clusters, the 
cells divide again and begin to differentiate into neurons (Sullivan and Beltz 2005). Once they 
have differentiated, local interneurons with their somata in Cluster 9 project to both the olfactory 
and accessory lobes, while projection interneurons in Cluster 10 project to either the olfactory or 
accessory lobe (Sullivan and Beltz 2005).  
Typically, stem cells are thought of as long-lived and self-renewing. The NIH defines a stem 








Figure 2: Schematic showing the neuronal precursor lineage. 
Neuronal precursors divide in the neurogenic niche, migrate and 
divide in the streams and arrive in the LPZ of Cluster 10 and the 
MPZ of Cluster 9, where they differentiate into neurons and 
project either to the olfactory and/or accessory lobe. Figure 




specialized cells” (http://stemcells.nih.gov/info/basics/Pages/Default.aspx). However, as stated 
above, BrdU labeling experiments show that both daughter cells of the 1
st
-generation neuronal 
precursors migrate away from the niche and towards the clusters (Benton, Chaves da Silva et al. 
2013). This would imply that since the niche contains only a few hundred cells, the neurogenic 
capacity of the crayfish would be quickly depleted. On the contrary, 1
st
-generation neuronal 
precursors are observed throughout the twenty-year life span of the crayfish, and the pool of 
precursors is never depleted (Benton, Chaves da Silva et al. 2013). Thus, if neuronal precursors 
in the crayfish niche are not self-renewing, yet are never depleted, the pool must be replenished 
by a source extrinsic to the niche (Beltz, Zhang et al. 2011). 
 
The immune system as the likely source of neuronal precursors 
The immune system is a logical source of neuronal precursors because the niche is an 
isolated structure that is surrounded by blood vessels, providing direct access for hemocytes (e.g. 
blood cells) to the niche. Multiple lines of evidence have recently emerged to support the 
immune system as the source of neuronal precursors in crayfish. In a first set of in vitro 
experiments by Benton et al. (2011), the attraction of cells from various organs of the crayfish 
Procambarus clarkii to the neurogenic niche was investigated. Hemocytes, as well as cells from 
the hepatopancreas, hematopoietic tissue, and green gland were labeled with CellTracker Green 
and co-cultured with whole brains that were desheathed to expose the niches. Of these cell types, 
only hemocytes were consistently attracted to the niche, indicating that cells from the immune 
system possess an intrinsic affinity for the neurogenic niche.  
In addition, the number of cells in the niche is influenced by the total number of circulating 




al. (2014) found that by ablating half of the HPT, the total hemocyte count decreased, as did the 
numbers of cells in the niche. However, it was also found that a recombinant-astakine 1 injection 
(described below) rescued both the numbers of circulating cells and the number of cells in the 
niche.   
Further, in vivo experiments by Benton et al. (2014) labeled hemocytes in “donor” crayfish 
with 5-ethynyl-2’-deoyuridine (EdU), a thymidine analog that is functionally similar to BrdU. 
Blood taken from donor P. clarkii and injected into an unlabeled recipient resulted in EdU-
labeled cells in the niche, streams, and clusters on successive days. These cells eventually label 
for orcokinin in Cluster 9 and SIFamide in Cluster 10, the transmitters typically expressed by 
neurons in these areas (Benton, Kery et al. 2014).  These data demonstrate that hemocytes have 
the capacity to generate cells with neuronal properties in the adult brain. 
 
The crayfish immune system    
Unlike mammals, crayfish possess only an innate immune system (Soderhall, Kim et al. 
2005). The fact that crayfish lack an adaptive immune system is potentially beneficial to our 
research as it decreases the likelihood of crayfish rejecting a blood transfusion. The crayfish 
hemolymph is composed of three cellular classes, the relatively undifferentiated phagocytic 
hyaline cells, phagocytic semi-granular cells and granular cells, involved in fighting off microbes 
(Soderhall 2013). The precursors for hyaline, semi-granular, and granular cells are produced by 
immune tissue through a process called hematopoiesis. The immune system tissue is composed 
of two regions, the posterior hematopoietic tissue (HPT) and the anterior proliferation center 




dorsal surface of the stomach and have direct access to the brain through the dorsal artery (Figure 
3).  
The HPT is a highly proliferative region and 
consists of approximately 1.4E6 cells adhered both 
to an extracellular matrix and in tear-drop shaped 
aggregates termed lobules (Chaga, Lignell et al. 
1995; Soderhall, Bangyeekhun et al. 2003). Five 
types of cells are known to mature in the HPT in 
preparation for release into the hemolymph. Type 1 
cells are relatively undifferentiated, type 2 cells are 
precursors to both semi-granular and granular cells, 
types 3 and 4 are precursors to granular cells and 
type 5 cells are precursors to the semi-granular cells 
(Chaga, Lignell et al. 1995; Soderhall 2013).   
The APC is a region of the immune system 
located in the cor frontale (auxiliary heart), that is 
highly vascularized and has direct access to the 
brain through the dorsal median artery (Figure 3) 
(Noonin, Lin et al. 2012, Chaves da Silva, Benton 
et al. 2013). Like the HPT, cells in the APC are 
highly proliferative (Noonin et al. [2012] found 
















Figure 3: Schematic of the crayfish 
immune system. A: diagram of the 
immune tissue sitting on top of the 
crayfish stomach (DMA= dorsal median 
artery). B: Image of dissected immune 
system tissue showing the APC, HPT, 
brain, and DMA. Figure adapted from 






unlike the HPT, many of these cells are distributed into rosettes, structures thought to be related 
to stem cells whose progeny will have an ectodermal fate (Chaves da Silva, Benton et al. 2013).  
 
Regulation of the crayfish immune system: 
      The ability to regulate the release and production of blood and immune cells is vital to fight 
off infection and for general, every-day survival of an organism. Soderhall (2013) describes 
astakine 1, a cytokine and a prokineticin (mammalian) homologue that is involved in regulating 
the differentiation and release of cells from immune tissue into the circulation (Lin, Novotny et 
al. 2010, Noonin, Lin et al. 2012, Soderhall 2013). Prokineticins are a family of proteins 
involved in, among other things, the regulation of the immune system, neural development, 
circadian cycles and angiogenesis (Zhou 2006; Zhou and Meidan 2008; Watthanasurorot, 
Soderhall et al. 2011).  Cytokines are signaling proteins released by the immune system that 
regulate an immune response (Cannon 2000). Astakine 1 is a cytosine-rich protein first 
discovered for its role in increasing immune cell proliferation in the crayfish Pacifastacus 
leniusculus. This molecule also prevents apoptosis of cells in the immune tissue by controlling 
levels of crustacean hematopoietic factor (CHF) and promotes the differentiation of immature 
cells into semi-granular cells (Noonin, Lin et al. 2012, Soderhall 2013). Endogenously, astakine 
1 is found in HPT cells, hemocytes, specifically semi-granular cells, and nerve tissue (Soderhall, 
Kim et al. 2005; Lin, Novotny et al. 2010). For experimental purposes, astakine 1 has been 
sequenced and a recombinant astakine-1 (r-AST1) has been produced by the Soderhall lab (Lin, 
Novotny et al. 2010, Soderhall 2013). 
       Experiments have shown that astakine 1 is upregulated in the crayfish after injury or 




response and in keeping the numbers of circulating hemocytes balanced. In addition, an injection 
of r-AST1 increased the total hemocyte count of crayfish, while RNA interference studies 
showed that silencing astakine 1 resulted in reduced numbers of hemocytes and eventually in the 
death of the crayfish (Soderhall 2013). Further, unpublished data (Soderhall Lab) indicates a 
connection between astakine 1 and serotonin regulation in the crayfish Pacifasticus lenisculus. 
     Astakine 1 controls immune cell release in the crayfish by regulating transglutaminase, a 
protein in the HPT that essentially glues immune cells to the HPT’s extracellular matrix by 
binding with collagens. Transglutaminase is also known to prevent the maturation of HPT cells. 
Astakine 1 prevents the action of transglutaminase and thereby promotes the maturation and 
release of hemocytes by the HPT into the circulation (Watthanasurorot, Soderhall et al. 2011). 
More specifically, astakine 1 causes the maturation of cells by inducing the secretion of PlRunt, 
a molecule characteristic of semi-granular and granular cells (Watthanasurorot, Soderhall et al. 
2011).  Recent experiments in P. clarkii have shown that at room temperature, r-AST1 causes a 
release of cells from the immune system and into the circulating hemolymph 12 hours post-
injection (Benton, Kery et al. 2014). 
 
Current Experiments: 
As described above, neuronal precursors in the crayfish niche are not self-renewing, yet are 
also never depleted, indicating that they arrive in the brain from a source extrinsic to the niche. 
The studies described here further tested the finding that the immune system replenishes the 
supply of neuronal precursors in the neurogenic niche in crayfish. Thus, the first of the three 
experiments described in this paper is predicated on the fact that if, in fact, the neuronal 




labeled cells should be present in the niche immediately following the pulse and then again at a 
later time point once the cells that are labeled in the source tissue are released and have migrated 
to the niche. This experiment, using a single pulse of BrdU, also examined BrdU-labeling 
patterns in the HPT and APC at various time points for three weeks following the injection to 
determine if there is a release of labeled cells from these tissues that corresponds to the arrival of 
BrdU-labeled cells in the niche. Additionally, a single pulse of 5-Ethynyl-2’-deoxyuridine (EdU) 
was used to determine the pattern of hemocyte labeling over the three weeks. EdU and BrdU 
have the same functionality, but EdU is visualized using a chemical method instead of the 
immunohistochemical method used to visualize BrdU. Thus, since hemocytes are known to have 
a high affinity for secondary antibodies, EdU is more reliable than BrdU to count hemocytes. 
In two additional experiments, r-AST1 was used to definitively test whether promoting the 
release of cells from the immune system affects the timeline by which neuronal precursors re-
appear in the neurogenic niche of the crayfish P. clarkii. Indeed, these experiments demonstrate 
that the arrival time of BrdU-labeled precursors in the niche can be manipulated by altering the 
timing of r-AST1 injection into crayfish, providing direct evidence that the immune and nervous 
systems are linked and strongly suggesting that the released immune system cells become 
neuronal precursors.  
Using the same BrdU labeling technique and dissection timeline protocol as in the first 
experiment, r-AST1 was injected either in conjunction with or 24 hours following BrdU 
injection. The timeline by which BrdU-labeled (newborn) cells are present in the niche and the 
fraction of cells in the APC and HPT that are BrdU-labeled were determined and compared 
between the BrdU only experiment and the two experiments with varying times of r AST1 vs 




system, on both the numbers of BrdU-labeled cells in tissues of the immune system and in the 
niche were determined in order to evaluate the relationship between the release of hemocytes 
from immune tissues and the appearance of neuronal precursor cells in the niche. 
It is also of current interest in our lab to determine the pathway by which cells travel as they 
are born and released from the immune tissues. Possible hypotheses include that cells migrate 
from the APC to the HPT where they mature in the lobules before being released into the 
hemolymph, or that both the APC and HPT directly release cells into the hemolymph. In 
addition, it is possible that cells enter the niche either from the circulation or through the dorsal 
median artery that connects the APC to the brain. Thus, the experiments described here aim to 

















Materials and Methods 
Animals 
 Procambarus clarkii, a species of freshwater crayfish, were used for all experiments and 
were housed in the Wellesley College Animal Care Facility. Throughout the experiments, the 
animals were kept in freshwater aquariums on a 12/12 light/dark cycle with artificial plants, and 
PVC tubing and ceramic mugs for shelter. During the first set of experiments, all animals were 
fed on Tuesday and Friday mornings and during the second and third sets of experiments they 
were fed more frequently (Monday, Wednesday and Friday), in order to decrease cannibalism. 
All animals had a carapace length of approximately 30-35mm. Both male and female animals 
were used in all experiments, although these were not scored independently, and pregnant 
females were removed from the cohort.  
Injection protocols 
Experimental series 1: BrdU-only experiment 
 P. clarkii were injected in the morning of day 0 with 100μL of BrdU (5mg/mL in saline). 
In addition, Jingjing Li also injected P. clarkii with 100 μL of 0.1mg/mL EdU. 
Experimental series 2: Simultaneous BrdU and r-AST1 injection paradigm 
An Escherichia coli system was used to synthesize recombinant-astakine 1 (r-AST1) in 
the lab of Irene Soderhall as described in Lin, Novotny et al. 2010, and the r-AST1 product was 
shipped to the Beltz Lab. P. clarkii were injected at 0930 on day 0 with 70 μl of 2.8E-3mg/mL r-
AST1 (a concentration used in and determined for Benton et al. (2014)), and 100μL of 5mg/mL 
BrdU administered through the same syringe so that the animal would only receive one injection, 





Experimental series 3: 24-hour delay between BrdU and r-AST1 injection paradigm 
P. clarkii were injected with 100μL of 5mg/mL BrdU at 1000 on day zero and returned to 
the animal care facility overnight to ensure consistent light/dark cycles. At 1000 on day one, 
after the removal of 5 animals for day 1 dissections, the remaining animals were injected with 
70μL 3.08E-3mg/mL r-AST1. 
Dissection protocols 
 Brains with attached niches and immune system tissues (APC and HPT) were dissected 
and fixed overnight at 4°C in 4% paraformaldehyde in 0.1M phosphate buffer [20mM NaH2PO4, 
80mM Na2HPO4; pH 7.4 (Benton et al. 2014)]. Brains in all three experiments were dissected on 
days 1-8, 10, 14 and 21. In the BrdU-only experiment APCs were dissected on days 1-5, 8, 10, 
14 and 21 and HPTs on days 1-8, 10, 14 and 20. In the simultaneous injection protocol APCs 
were dissected on days 1-8, 14, and 21 and HPTs on days 1-8, 10, 14, and 21. In the r-AST1 
delay experiments APCs were dissected on days 1-2, 4-8, 10, 14 and 21 and HPTs were 
dissected on days 1-8, 10 and 14. 
Immunohistochemical labeling 
 Brains, APC, and HPT were removed from fix, rinsed for 1.5 hours in 0.3% Triton in 
0.1M phosphate buffer (PBTx), soaked in 2N HCl for 30 minutes, and rinsed again in PBTx for 
1.5 hours. Brains were then incubated overnight at 4°C in rat anti-BrdU (1:50; Accurate 
Chemical OBT0030G) and mouse anti-glutamine synthetase (GS; 1:100 BD Biosciences: 
610517) primary antibodies. APC and HPT were incubated overnight at 4°C in a mouse anti-
BrdU antibody conjugated with AlexaFlour 488 (1:20) (Life Technologies: B35130). All tissues 
were then rinsed again in PBTx for 1.5 hours. Brains were then incubated overnight at 4°C in 




Jackson Immuno Research) secondary antibodies and then rinsed for 1.5 hours in PBTx. All 
tissues were incubated for 10 minutes in propidium iodide (PI; 1:100 in PBTx), rinsed again for 
1.5 hours in PBTx and then mounted using FlouroGel with tris buffer (17985-11) mounting 
medium and allowed to set for two days at room temperature prior to storage at 4°C. Brains were 
mounted with their ventral side towards the coverslip. 
Data Collection 
 All tissue preparations were analyzed using a Leica TCS SP5 confocal microscope. An 
image was taken bilaterally at points A and B (Figure 4) in each APC and an image was taken 
bilaterally at the posterior region of each HPT, adjacent to the dorsal sinus (Figure 4). These 
regions were chosen due to their known proliferative nature and for the presence of landmarks in 
the tissue (the muscles of the APC and dorsal sinus in the HPT) that allow approximate 
standardization of the location of these sampling sites. Each image was taken at 40X 
magnification, magnified an additional 3.00 
times. A 4 μm stack of 1.0 μm thick images was 
taken at each location and rendered as a 
maximum projection in 2D for analysis.  
Figure 4: Schematic of dissected tissue regions and 
labeling sites. In the APC, 4 images were taken per 
animal, bilaterally at region A and region B adjacent to the 
muscles (shown in purple). In the HPT, 2 images were 
taken per animal (location circled in red) at the posterior 
end of the HPT, adjacent to the dorsal sinus. Images in all 
locations were taken at 40X magnification with an 
additional 3.00 times zoom. Each image was 4 μm thick. 
















Determining the number of BrdU-labeled cells in a niche 
A cell in the niche was considered to be BrdU-labeled if it fluoresced at 488 nm, was 
labeled with PI, and was surrounded by GS immunoreactivity, which is found in the cytoplasm 
of all niche cells (Figure 5). This was determined by examination with the Leica software on the 
confocal microscope. The percent chance of finding 
a BrdU-labeled cell in the niche was determined by 
dividing the number of niches that possessed any 
number of BrdU-labeled cells by the total number 
of niches.  
Figure 5: Representative image of a niche with a BrdU-
labeled cell. The niche is outlined in blue (GS), PI is red, and 
the labeled cell is denoted by green labeling and a white 
arrow. 
Determining BrdU-labeling in the APC and HPT 
 After all imaging was complete, the maximized, 2D stacked images of each APC and 
HPT region were transferred to a laboratory computer and the number of PI-labeled cells and the 
number of BrdU-labeled cells were counted independently (Figure 6). To make these counts, a 
transparency was taped to the computer screen and each cell was circled by hand and counted. In 
order to obtain a percentage of BrdU-labeled cells for each tissue region, the number of BrdU-
labeled cells was divided by the total number of PI-labeled cells for each image. For analysis, the 
four regions sampled in each APC in one animal were averaged and counted as one “n”; 
likewise, and the two regions sampled from the HPT in one animal were averaged and each 
animal was counted as a single “n”. It should be noted that, due to methodological constrains, at 




Thus, some averages represent fewer than the 
maximum number of counts. However, given the 
relatively small variability in these counts, these 
samples can still be confidently included in the 
data set. 
Figure 6: Representative 2D, stacked 4 μm thick 
APC/HPT image. Top left: PI-labeled cells. Top right: 
BrdU-labeled cells. Bottom left: overlay of BrdU-labeled 
and PI-labeled cells. (40X, zoom 3.00). 
 
Determining EdU-labeling in Hemocytes 
Hemocyte samples were taken on days 1, 3, 5, 10, and 17 following injection. The Click-
iT Alexa Flour 488 Imaging Kit was used to visualize EdU in hemocytes drawn from animals 
and placed on a slide such that they were one layer thick.  3 sample regions on each slide were 
visualized using confocal microscopy at 40X, zoom 3.00, and the percentage of cells labeled 
with EdU was determined.    
Statistical analysis 
 A One-Way ANOVA was performed using JMP software to determine whether any 
differences existed in the percent of BrdU-labeled cells on day 1 in the APC across all three 
experimental protocols and in the HPT across all three experimental protocols. Data are 









 In order to determine the timeline by which BrdU-labeled cells are found in the niche, a 
cohort of P. clarkii were injected with 5mg/mL BrdU and their brains were taken on days 1-8, 
10, 14, or 21 post-injection. As expected, due to a niche cell cycle time of approximately two 
days and a BrdU clearing time of approximately two days, immunohistochemical labeling 
revealed BrdU-labeled cells in the niche on days 1-4 post-injection (peak A), but no BrdU-
labeled cells on days 5-7 post-injection (Figure 7A). However, as shown in Figure 7A, BrdU-
labeled cells were again present in the niche on days 8-14 (peak B) following BrdU-injection.  
By day 5 post-injection, due to BrdU clearing and the cell cycle times, the cells that were 
labeled in the niche would have divided and migrated into the streams; hence there is a gap in 
labeling between days 5 and 7. This lack of BrdU labeling confirms that BrdU is not retained in 
the niche cells, and also means that the BrdU-labeled cells that appear in the niche on days 8-14 
must have been labeled in a source tissue extrinsic to the niche. The source tissue would have 
been labeled at the time of BrdU injection, and the labeled neuronal precursor cells released from 
that tissue would then have migrated to the niche.  
Given the evidence pointing to the innate immune system as a source of neuronal precursors 
in the crayfish, it was hypothesized that the timing of peak B could be manipulated with astakine 
1, an immune system modulator known to cause the release of immune system cells 12 hours 
after injection (Benton, Kery et al. 2014).  Thus, the labeling experiment was repeated, this time 
with a simultaneous injection of 5mg/mL BrdU and r-AST1 on day 0, in order to test whether the 
timing of appearance of BrdU-labeled cells seen in the niche on days 8-14 (peak B) was altered. 
We hypothesized that, if the immune system is indeed the source of neuronal precursors, the 




due to the release of cells from the immune system tissue 12 hours after r-AST1 injection 
(Benton, Kery et al. 2014). In other words, the injection of r-AST1 was predicted to close the 
“gap” between peaks A and B (i.e., the BrdU-labeled cells in the niche on days 1-4 following 
BrdU injection [presumably labeled as they were going through S phase in the niche], and the 
cells labeled in the source tissue that take time to be released into circulation and migrate into the 
niche on days 8-14).  
As shown in Figure 7B, following a simultaneous injection of BrdU and r-AST1 on day 0, 
BrdU labeled cells are present in the niche at all sampled time points (there is no longer a gap 
period), with peaks on days 2, 4, 7 and 10 post-injection (peaks C-F in Figure 7B).  
To further confirm that manipulation of the immune system via introduction of r-AST1 
caused the change in the timing by which BrdU-labeled cells are seen in the niche, the timeline 
labeling experiment was again repeated, this time with an injection of 5mg/mL BrdU on day 0 
and an injection of r-AST1 on day 1. It was hypothesized that if peak E in Figure 7B is due to the 
release of BrdU-labeled cells from the immune system 12 hours after r-AST1 injection, injecting 
r-AST1 24 hours later would cause peak E to shift 24 hours to the right, thus definitively 
showing that the timeline by which BrdU-labeled cells appear in the niche can be controlled by 
manipulating the differentiation and release of cells from the immune system. 
As shown in Figure 7C, following BrdU injection on day 0 and r-AST1 injection 24 hours 
later, BrdU-labeled cells are present in the niche on all sampling days with peak maxima on days 
1, 4 and 14 post-injection (labeled in Figure 7C as peaks G-I).  
 Figure 7D shows a comparison of the percent chance of finding BrdU-labeled cells in the 
niche across all three experimental protocols. Peak E after simultaneous injection of BrdU and r-




E is due to the release of immune system cells. A comparable peak 24 hours later, as 
hypothesized, is not identifiable when r-AST1 was injected 24 hours after BrdU. However, peak 
I is wider (spanning 14 days) and 43.33% taller than peak B, indicating an increase in BrdU-
labeled cells and a possible delay in cells corresponding to peak E such that these combined with 
peak B to form peak I.  
 Finally, as seen on the right Y-axes of Figure 7A-C, the average number of BrdU-labeled 
cells found in a niche at each time point roughly follows the pattern of the percent chance of 












































































































































































































































































































































































































































  In order to characterize the activity of immune system tissues and their response to r-AST1 
injection, the percent of cells in the APC and HPT that were labeled with BrdU at days 1-8, 10, 
14 and 21 in each of the three experimental protocols was determined. As shown in Figure 8, the 
percent of cells labeled with BrdU in the APC decreases exponentially with time in the BrdU-
only protocol. In contrast, the percent of cells labeled in the HPT remains constant over the first 
three days after BrdU injection, then quickly drops off. The decrease of BrdU-labeled cells in the 
immune system tissues is followed by an increase of BrdU-labeled
 
cells in the circulating 
hemolymph (Figure 8), and then by the subsequent appearance of BrdU-labeled cells in the niche 
(e.g., peak B [Figure 7]).  
Figure 8: The percent of BrdU-labeled cells in the immune tissues (APC and HPT) decreases prior 
to an increase of EdU-labeled cells in the circulating hemolymph and the subsequent reappearance 
of BrdU-labeled cells in the niche. After a single injection of BrdU on day 0, brains, APC and HPT were 
dissected on days 1-8, 10, 14 and 21 post injection. The % chance of finding BrdU labeled cells in the 
niche as well as the % of cells that were BrdU-labeled in the HPT and APC was determined for each time 
point. BrdU labeling decreases exponentially in the APC but remains constant for days 1-3 in the HPT 
before severely dropping on day 4. BrdU-labeled cells are found in the niche days 1-4 and again days 8-
14 post-BrdU injection. In addition, following an EdU injection, the numbers of circulating EdU-labeled 
hemocytes on days 1, 3, 5, 10 and 17 was determined: day (d)1n=3, d3n=4, d5n=4, d10n=2, 




In the simultaneous injection of BrdU and r-AST1 protocol, the percent of cells labeled 
with BrdU in the APC remains relatively constant between days 1 and 2 and then drastically 
drops to near negligible amounts on subsequent days (Figure 9). Similarly, the percent of cells 
labeled with BrdU in the HPT remains level on days 1 and 2 and then drops sharply on day 3 to 












Figure 9: The percent of BrdU-labeled cells in the immune tissues (APC and HPT) remains constant on days 
1 and 2 and then decreases sharply prior to the second, third and fourth labeling peaks in the niche. After a 
simultaneous injection of BrdU and r-AST1 on day 0, brains, APC and HPT were dissected on days 1-8, 10, 14 and 
21 post-injection. The % chance of finding BrdU labeled cells in the niche as well as the % of cells that were BrdU-
labeled in the HPT and APC was determined for each time point. BrdU-labeled cells are found in the niche on all 








In the third protocol, with a 24 hour delay between BrdU and r-Ast 1 injection, the 
percent of BrdU labeled cells in both the APC and the HPT rises and falls, with peaks on days 2, 
5, and 7 in the APC and on days 3, and 6 in the HPT, before dropping by day 10 (Figure 10). 
Figure 10: Following a BrdU injection on day 0 and a r-AST1 injection on day 1 the percent of BrdU-labeled 
cells in the immune tissues (APC and HPT) fluctuates on days 1-7 before dropping on day 8, prior to the peak 
in BrdU labeling in the niche on day 14. Brains, APC and HPT were dissected on days 1-8, 10, 14 and 21. The % 
chance of finding BrdU labeled cells in the niche as well as the % of cells that were BrdU-labeled in the HPT and 
APC was determined for each time point. BrdU-labeled cells are found in the niche on all days with peaks on days 1, 
4 and 14.  
In order to determine the effect of r-AST1 injection on the APC and HPT, the BrdU 
labeling patterns in each tissue for each of the three protocols were plotted against one another as 
shown in Figures 11 and 12.   
Following simultaneous BrdU and r-AST1 injection and delayed injection of r-AST 1, 
there is a significant drop in BrdU-labeled cells on day 1 in the APC as compared to the BrdU 




only/Simultaneous r-AST1 p=0.0103, BrdU only/r-AST1 delay p=0.0490, Simultaneous r-
AST1/r-AST1 delay p=0.3808).  In addition, whereas the percent of labeled cells in the APC in 
the BrdU only and simultaneous injection protocols decreases and does not rise again, there are a 
series of peaks and troughs in the percent of BrdU-labeled cells following the initial decrease of 
















Figure 11: BrdU labeling patterns in the APC across all three experimental protocols. Following either an 
injection of BrdU on day 0, a simultaneous injection of BrdU and r-AST 1 on day 0, or an injection of BrdU on day 
0 followed by an injection of r-AST 1 on day 1, APCs were dissected from P. clarkii on days 1-8, 10, 14, and 21. 
Samples were taken at four regions of each APC and averaged together as a single sample (shown as average +/- 
SD). There is a significantly larger percentage of cells labeled on day one in the BrdU only protocol than in both the 
BrdU only and the simultaneous BrdU an r-AST 1 injection protocol (ANOVA, F=8.2446, df=2,11, P=0.0065; 
Tukey HSD test, BrdU only/Simultaneous r-AST1 p=0.0103, BrdU only/r-AST1 delay p=0.0490, Simultaneous r-
AST1/r-AST1 delay p=0.3808) For the BrdU only protocol: day1n=8, d2n=8, d3n=7, d4n=6, d5n=6, d6n=0, d7n=0, 
d8n=3, d10n=4, d14n=4, d21n=4. For the simultaneous injection protocol: d1n=2, d2n=3, d3n=4, d4n=4, d5n=4, 
d6n=2, d7n=3, d10n=0, d14n=1, d21n=4. For the delay protocol: d1n=4, d2n=4, d3n=0, d4n=3, d5n=2, d6n=3, 




In the HPT the percent of BrdU-labeled cells on day one does not differ significantly  
across all experiments (Figure 12) (ANOVA, F=0.2338, df=2,8, P=0.7967; Tukey HSD test, 
BrdU only/Simultaneous r-AST1 p=0.7877, BrdU only/r-AST1 delay p=0.9265, Simultaneous r-
AST1/r-AST1 delay p=0.9867) In addition, while the BrdU-labeling in the HPT in the BrdU-
only protocol is stable over the first three days before dropping, there is a small peak in labeling 
on day 2 in the simultaneous injection protocol and in the delay injection protocol. In addition, 
whereas the percent of BrdU labeling decreases and does not rise again in the BrdU only and 
simultaneous injection protocols, the labeling peaks again on day 6 in the 24 hour delay protocol.  
Figure 12: BrdU labeling 
patterns in the HPT 
across all three 
experimental protocols. 
Following either an 
injection of BrdU on day 
0, a simultaneous injection 
of BrdU and r-AST 1 on 
day 0, or an injection of 
BrdU on day 0 followed 
by an injection of r-AST 1 
on day 1, APCs were 
dissected from P. clarkii 
on days 1-8, 10, 14, and 
21. Samples were taken at 
two regions of each HPT 
and averaged together as a 
single sample (shown as 
average +/- SD). For the BrdU only protocol: day1n=5, d2n=4, d3n=3, d4n=5, d5n=4, d6n=5, d7n=6, d8n=2, 
d10n=2, d14n=3, d20n=4. For the simultaneous injection protocol: day (d) d1n=4, d2n=4, d3n=4, d4n=2, d5n=3, 
d6n=3, d7n=5, d8n=3, d10n=2, d14n=2, d21n=5. For the delay protocol: d1n=2, d2n=5, d3n=1, d4n=3,  d5n=2, 









 The results of three experimental protocols are presented in this thesis: injection of BrdU 
at day 0, injection of BrdU and r-AST1 simultaneously at day 0, and injection of BrdU on day 0 
followed by injection of r-AST1 on day 1. The effects of these three protocols on BrdU-labeled 
cells in the niche, APC and HPT were observed at standardized time points over a 21 day period.   
The resulting data show that manipulating the innate immune system of P. clarkii alters the 
timeline by which BrdU-labeled neuronal precursors are present in the neurogenic niche.   
 When P. clarkii were injected only with BrdU on day 0, BrdU-labeled cells were present 
in the niche on days 1-4 and 8-14 post-injection (Figure 7A). The observed labeling on days 1-4 
was expected for a combination of reasons: (1) there is a constant population of dividing cells in 
the neurogenic niche that would label with BrdU; (2) the cell cycle time in the niche is 
approximately two days and the clearing time for BrdU in the niche is also approximately two 
days (Benton et al., 2011). In other words, there is a two day window during which the levels of 
BrdU are sufficient in the niche for a cell going through S-phase to incorporate the label at a 
detectable concentration. But, since it takes 2 days for the last labeled cells to divide and exit the 
niche, there is approximately a four day window during which cells intrinsic to the niche at the 
time of injection could have incorporated BrdU. As expected and as shown in Figure 7A, no 
BrdU-labeled cells were found in the niche by 5 days post-injection.  
 This experiment, however, showed that BrdU-labeled cells are again present in the niche 
on days 8-14 following BrdU injection. However, due to the clearing time of BrdU and the cell 
cycle time of cells in the niche, the cells composing this late peak (peak B in Figure 7A) could 
not have been labeled in the niche. Instead, these cells must have been BrdU-labeled in their 




extrinsic source of neuronal precursors and suggest that, since labeled cells did not reappear in 
the niche until day eight, it takes approximately eight days for cells to be released from their 
source tissue, migrate, mature and arrive in the niche.  
 There is strong in vitro and in vivo evidence that this extrinsic source of neuronal 
precursors in crayfish is the innate immune system. In vitro evidence shows that hemocytes 
(blood cells) and no other cell type are attracted to the niche in culture (Benton, Zhang et al. 
2011). Additionally, in vivo evidence shows that the numbers of cells in the niche are tightly 
correlated with the total number of circulating hemocytes, as evidenced by the decrease in both 
cell populations following partial HPT ablation, and the subsequent rescue of both cell 
populations following r-AST1 injection (Benton, Kery et al. 2014). Most importantly, EdU-
labeled hemocytes taken from a donor animal and injected into an unlabeled recipient animal 
generate labeled cells in clusters 9 and 10 that express tissue appropriate neuronal markers by 
seven weeks after transfer (Benton, Kery et al. 2014). Thus, the two r-AST1 injection 
experiments in this thesis tested whether or not manipulation of the innate immune system 
affects the appearance of BrdU-labeled neuronal precursors in the niche. If the source tissue is, in 
fact, the innate immune system, injection of r-AST1, an immune system modulator known to 
cause the release of hemocytes (specifically semi-granular cells [Noonin, Lin et al. 2012; 
Soderhall 2013]) into circulation 12 hours after injection (Benton, Kery et al. 2014) should cause 
BrdU-labeled cells that were labeled in the immune tissues to arrive at the niche faster than they 
would have in the absence of the r-AST1 injection. 
 As shown in Figure 7B, following a simultaneous injection of BrdU and r-AST1 on day 
0, BrdU-labeled cells are present in the niche on all sampling days, including on days 5-7 when 




niche on day 7, a day on which no labeled cells were observed in the BrdU-only protocol, best 
shows this effect. As previously stated, any BrdU-labeled cells found in the niche after day 4, 
could not have been labeled in the niche and must have migrated to the niche after being labeled 
elsewhere ---- in their source tissue. Thus, the cells observed on days 5-7, a time previously 
devoid of cells, must have been labeled in the source tissue prior to arrival in the niche. This 
supports the hypothesis that the BrdU-labeled cells appearing in the niche after day 4 are coming 
from immune system tissues as the only difference between the two protocols was the injection 
of r-AST1, an immune system modulator. These results also indicate that while cells normally 
take about eight days to be released from the source tissue, mature, and migrate into the niche, 
with the r-AST 1 injection, this circulation and maturation process is quicker.  
 In addition to the new peak at day 7 (peak E, Figure 7B) in the simultaneous BrdU and r-
AST1 injection protocol there is also a new peak on day 4 (peak D). While there was a 10% 
chance of finding labeled cells in the niche on day 4 in the BrdU only protocol, in this protocol 
there is a 50% chance. Given that r-AST1 is known to cause the differentiation and release of 
cells from immune tissue and into circulation 12 hours after injection, this new peak, along with 
the 17% and 13% chance of finding labeled cells on days 5 and 6, days where there was no 
labeling in the BrdU only protocol, could indicate that labeled cells from the immune tissue 
begin to arrive in the niche as early as 4 days post r-AST1 injection, with the majority of labeled 
cells ejected from the immune system by r-AST1 arriving on day 7 (peak E). This would indicate 
that instead of taking about eight days to circulate and mature, as seen in the BrdU-only protocol, 
labeled cells from the source tissue may take as little as four days to appear in the niche, but that 




 Alternately, the r-AST1 injection may have caused proliferation or self-renewing 
divisions of the intrinsic niche cells, thus causing the rise in both the percent chance of finding 
BrdU-labeled cells in the niche and in the average number of BrdU-labeled cells in the niche 
seen on day 4 (peak D). As shown by Benton et al. (2014), the numbers of BrdU-labeled cells in 
the niche rises significantly two days after injection r-AST1 injection. In the BrdU only protocol, 
peak A, showing the intrinsically labeled cells, lasts from day 1 to day 4. Following the r-AST1 
injection in the second protocol, this peak is still present, but instead it is composed of two local 
maxima (peaks C and D) and an elevated level even on day 5. Peak D and the small number of 
cells seen on day 5 may therefore represent a division in the labeled cells that were present in the 
niche on days 1-3. Then, the first cells arriving from the immune system would be those seen in 
peak E on day 7. Even though a rise in labeled niche cells is seen on day 2 in the work of Benton 
et al. (2014), these data are not inconsistent with the rise seen here on day 4 (peak D) given 
differences in animal size between the experiments.    
Another comparison of Figures 7A and B and Figure 7D shows a stark difference at day 8 
post-injection where in the BrdU-only protocol there was a 37.5% chance of finding labeled cells 
and in the simultaneous BrdU and r-AST1 protocol there was only a 10% chance. The BrdU-
labeled cells observed on day 8 in the BrdU-only protocol were the first cells to make it from the 
source tissue to the niche, meaning that they were likely completing S phase during the BrdU 
injection and were thus able to incorporate the marker and were likely also the most mature 
dividing cells. Thus, they would have been the first to be released from the immune system 
following BrdU injection and the first to reach the niche. Recall that r-AST1 causes the release 
of cells from the immune system tissue 12 hours after injection (Benton, Kery et al. 2014). Thus, 




without r-AST1 would have been the cohort that first arrived in the niche on day 8. The peak on 
day 7 and the trough on day 8 then in the simultaneous injection experiment is likely due to the 
fact that the r-AST1 injection may have specifically affected that set of most mature cells that 
would have been most ready for release, causing them to be released and to appear in the niche 
beginning on day 4, and peaking on day 7. The trough then at day 8 is likely due to the fact that 
the r-AST1 depleted the cells in the immune system that were mature enough to be released into 
circulation and that would normally have taken 8 days to arrive in the niche. We hypothesize that 
the peak on day 10 likely represents the next cohort of cells that matured enough in the immune 
system to be released, following the cohort whose release was expedited by the r-AST1. In other 
words, the trough at day 8 is likely due to a depletion of the immune system’s most mature cells 
caused by the r-AST 1 injection, a decrease in mature cells that took one to two days to restore 
before the cohort arriving in the niche at day 10 were mature enough to be released from the 
immune system tissue.   
Given these niche timeline experiments and previous in vitro and in vivo experiments 
showing that the extrinsic source of neuronal precursors is the innate immune system, the 
percentage of cells labeled in the two major innate immune system tissues, the APC and the 
HPT, was determined for each time point studied. In order for the labeled cells that appear in the 
niche after day 4 to have come from the immune system, we would have to see a decrease in the 
number of labeled cells in the immune system prior to the re-appearance of labeled cells in the 
niche.  
 As shown in Figures 8 and 9, the numbers of BrdU-labeled cells in both the APC and the 
HPT decrease overall with time to near negligible amounts by days 4-5 in both the BrdU only 




in the APC and HPT before the clearing time of BrdU incorporated the label and then were 
released from the tissues and into circulation. Figure 8 also shows that as the numbers of BrdU-
labeled cells in the immune tissues drop, the numbers of EdU-labeled cells in circulation 
increase, showing that the labeled cells are in fact released into the circulation, with their BrdU-
label.  
 As shown in Figure 8, while the overall trend is a decrease of BrdU-labeled cells in both 
tissues over time in the BrdU only experiment, the labeling decreases exponentially in the APC 
while it remains constant for the first three days before dropping near exponentially in the HPT. 
There are three possibilities for this plateau in labeling in the HPT. First, the cells from the HPT 
may be slower to mature and release after they pick up the BrdU-label, perhaps sitting in the 
HPT for three days after incorporating the label before release. Second, that the cell cycle time in 
the HPT may be equal to the release rate, causing release to be unnoticeable. And third, a 
hypothesis has been proposed that since the APC and HPT are connected, cells may migrate 
from the APC to the HPT, meaning that the release of cells from the HPT might not be 
noticeable on days 1-3 due to the fact that the tissue is being replenished by labeled cells from 
the APC.  
Comparison of niche labeling patterns in the BrdU-only and simultaneous BrdU/r-AST1 
injection shows that modulating the immune system clearly has an effect on the timeline by 
which BrdU-labeled cells from the source tissue appear in the niche. To further confirm this 
finding and to try to better determine which observed peaks were due specifically to the effects 
of r-AST1, a third protocol was devised in which BrdU was injected on day 0 and r-AST1 was 




expected that by delaying the r-AST1 injection by 24 hours, these peaks would shift 24 hours to 
the right.  
As shown in Figure 7C, using this protocol, BrdU-labeled cells were again observed at all 
tested time points, this time with peaks at days 1, 4, and 14. Notably, there is a trough in the 
percent chance of finding BrdU-labeled cells in the niche on day 2 and a stark increase of finding 
BrdU-labeled cells in the niche on day 4 (83.33%, up from 10% in the BrdU only protocol and 
50% in the simultaneous injection protocol (peak H; Figure 7D). As above, one possible 
explanation for this peak is the expedited release and early arrival of cells that were labeled in 
the source tissue, caused by the r-AST1 injection. However, again, if the effects of r-AST1 are 
strictly linear, peak D on day 4 in the simultaneous injection protocol should appear on day 5 in 
the 24 hour delay protocol, but instead Figure 7C shows a peak of increased height on day 4, and 
a trough on day 2 (down from day 2 in the BrdU only experiment by 11%).  
More likely, however, is the alternate explanation given above, that the r-AST1 injection 
induces intrinsically labeled niche cells to self-renew and/or divide, thus causing peak H. Given 
the likelihood that the neuronal precursors in the niche derive from the immune system, it is 
logical that r-AST1, an immune system modulator, would also have an effect on dividing niche 
cells. Of note, peak H is 33.33% higher than peak D, though I am here proposing that they are 
both caused by a secondary effect of r-AST1 that stimulates division of intrinsic niche cells. 
As a consequence of the delay between BrdU and r-AST1 injection in this protocol, the 
crayfish were put through the insult of two injections, whereas they only received one injection 
in the other two protocols. Evidence shows that a saline injection can temporarily increase the 
total hemocyte count (Noonin et al. 2012). Thus, the second injection on day 1 could have 




circulation. Future tests will be needed to determine whether there is an additive effect of the 
immune system response to an injection and to r-AST1. An additive effect between the increased 
total hemocyte count and the hemocyte release may have caused the increase from peak D to 
peak H under either hypothesis. 1) This may have caused more cells to arrive faster at the niche 
or 2) this may have induced a greater proliferation of the intrinsic niche cells. Given this 
discussion, it would be beneficial to re-do the BrdU only and simultaneous injection protocols 
with a sham injection of saline on day 1 to control for the non-specific effects of the injection on 
the immune system and total hemocyte count.  
Perhaps the most noticeable change between the simultaneous and delay injection 
protocols is the absence of the day 7 peak (peak E) that was likely caused by the day 0 r-AST1 
injection in the simultaneous injection protocol. Also noticeable is that peak I, between days 10 
and 21, is taller and wider than peak B from the BrdU only protocol. Since both peak B and peak 
I are past the four day window during which BrdU-labeled cells intrinsic to the niche could have 
been labeled in the niche, cells in both peak B and I were labeled in the source tissue and then 
migrated to the niche. There is an increase in the percent chance of finding BrdU labeled cells in 
the niche from 40% to 62.5% on day 10 and from 17 % to 80% on day 14 between the BrdU 
only protocol and the BrdU, 24 hour delay r-AST1 protocol. If the effect of r-AST1 were strictly 
linear, it would have been expected that peak E on day 7 of the simultaneous injection protocol 
would have shifted to day 8 in the delay injection protocol, causing the graph to look similar to 
that in the BrdU only protocol, perhaps with an increased chance of finding BrdU-labeled cells 
on day 8 if the r-AST1 caused more cells than those that would normally be in the cohort of cells 




 The fact that multiple injections may have stressed the animal and caused an immune 
response in addition to that caused by r-AST1 may explain why peak I does not appear until day 
10 when it would have been expected at day 8. Looking at Figures 8, 9, 11 and 12 it is clear there 
is a stark difference in the BrdU-labeling patterns in the APC and HPT between the two single-
injection protocols and the double- injection protocol. While overall the labeling in both tissues 
decreases with time and has decreased to near negligible amounts by day 3 (simultaneous 
protocol) or day 4 (BrdU only protocol) with little fluctuation after the start of the decline, the 
percent of BrdU-labeled cells in the delayed r-AST1 injection protocol fluctuates with a second 
major peak in both HPT and APC before beginning a steep decline on day 8. These fluctuations 
suggest that there are two important variables in the delayed r-AST1 injection protocol: the 
introduction of r-AST1, and the two injections. It is hypothesized that the effects of the injection 
and the r-AST1 are additive. In other words, the initial injection of BrdU on day 0 may have 
“primed” the immune system, and the second injection of r-AST1 on day 1 may have resulted in 
a magnified response to the cytokine, prompting divisions of cells in the APC/HPT and resulting 
in the secondary labeling peaks in these tissues.  
 Given that the BrdU-only protocol demonstrated that it takes eight days for cells that are 
released from the immune system to arrive in the niche, the second major peak in APC/HPT 
labeling explains why peak I has its maximum at day 14. As shown in figure 10, the second 
major peak in APC/HPT BrdU-labeling occurs at day 5 in the APC and day 7 in the HPT. The 
subsequent drop in labeling suggests that cells labeled in this second wave are released into the 
circulation in a fashion similar to those in the first wave. Thus, it would be expected that these 
cells would arrive in the niche approximately eight days after release, on day 13 or 15. As shown 




day 14, as expected according to this prediction. Peak I is then likely composed of cells 
migrating to the niche following the release of cells from the first and second labeling maxima 
(due to the possible additive effects of the r-AST1 and second injection), explaining why peak I 
is both wider and higher than peaks B and F. 
 It is also of interest to determine the pathway by which cells are released from the 
immune system prior to migrating to the niche. Looking at a comparison of the APC labeling 
patterns across the three protocols, Figure 11 shows a significant difference between the percent 
of labeled cells in the APC on day 1 between the BrdU only protocol and both the simultaneous 
and delayed r-AST 1 injection protocols. This is contrary to expectation given that on day 1 
animals in the BrdU only protocol and in the delay protocol had received the same treatment. 
However, there is a very large standard deviation in data from day one of the delay experiment 
and a relatively small sample size, indicating that if there were a larger sample size, the percent 
of labeling should not have differed from that of the BrdU only protocol on day one. Since r-
AST1 causes the release of cells from the immune tissue 12 hours after injection the fact that the 
percent of labeling on day one in the APC of the simultaneous injection protocol was 
significantly lower than that of the BrdU only protocol (and theoretically the delay protocol) 
indicates that the injection of r-AST1 causes the release of cells specifically from the APC 12 
hours injection.  
 As shown in Figure 12, the percent of labeling in the HPT on day 1 does not change 
drastically between the three protocols, again indicating that the release 12 hours after r-AST1 
injection is from the APC and not from the HPT. Additionally, there is a peak at day 2 in both 
the simultaneous injection experiment and in the delay experiment that was not present in the 




be released from the APC into circulation, but that cells released from the APC may also migrate 
into the HPT prior to release. This migration of cells from the APC to the HPT following r-AST1 
injection is even more likely given the fact that the peak in the simultaneous protocol is one day 
before the peak in the delay protocol and the r-AST1 injection in the simultaneous protocol was 
one day before that in the delay protocol. Alternatively, r-AST1 may promote the division of 
HPT and APC cells, resulting in the increases in observed counts.  
 In addition, Figure 12 shows that the initial drop in BrdU labeling in the HPT occurs on 
day 4 in the BrdU only protocol, day 3 in the simultaneous injection protocol, and day 4 in the 
delay protocol. The shift of release of cells to one day earlier in the simultaneous injection 
protocol than in the BrdU only protocol and the fact that the percent of labeled cells was not 
altered on day 1 as it was in the APC, suggests that the immediate effect of r-AST1 on the 
increase in total hemocyte count 12 hours after injection occurs because of release of cells from 
the APC.  In addition, there may be a downstream effect in the HPT where release of cells does 
not occur until day 3 after r-AST1 injection, again giving credence to the possibility that cells are 
move from the APC to the HPT in addition to being released directly into circulation from the 
APC.  
Conclusions 
 Overall, the three experimental protocols presented in the present paper 1) confirm 
definitively that neuronal precursors enter the niche from an extrinsic source; 2) that altering the 
timeline by which hemocytes are released from immune system tissues alters the timeline by 
which BrdU-labeled neuronal precursors appear in the niche; 3) that BrdU-labeled cells are 
released from both the APC and HPT and that these tissues are both potential sources of neuronal 




whereas it only alters cell release from the HPT approximately 3 days after injection. 
Collectively, these findings support those from Benton et al. (2011) and Benton et al. (2014) that 
the innate immune system is the source of neuronal precursors in the crayfish P. clarkii and show 
that these cells enter blood circulation prior to their migration into the niche.  
 
Future studies. Further studies should be done to determine whether r-AST1 also stimulates 
division of the intrinsic niche cells. Planned experiments will place a desheathed brain in a dish 
with r-AST 1, to determine whether the cytokine alone, in the absence of hemocytes will cause 
an increase in the number of cells in the niche via direct effects on the niche cells. 
 In addition, experiments should be done to better define the roles of the APC and HPT in 
neuronal precursor production. This could be done by dissociating the APC and HPT and placing 
their cells into separate cell cultures with brains and their associated niches. The cultures would 
then be observed for cell attraction to the niche. However this would be inconclusive in 
determining the origin of the precursors if they originate in the APC, but are released from the 
APC both directly and by way of the HPT as the results of the current paper suggest. 
 In addition, it is of interest to characterize the immune cell(s) that later becomes a 
neuronal precursor. This work is currently being performed in our lab using Percoll gradients 
which allow for the separation of hemocytes by type. Each class of hemocyte (if they are labeled 
prior to separation) can then be injected back into a crayfish and the niche examined for the 
presence of labeled cells at intervals after the transfer, to identify the specific cell type that 
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